Scientists Explore Whether Aging Itself Could Become a Medical Target
Goldlaner.com – For decades, medicine has largely treated the consequences of growing older: diabetes, heart disease, cancer and other chronic illnesses. A growing field of research is asking whether the biological processes that help drive those conditions might one day be addressed earlier, before disease becomes apparent.
The ambition is not simply to extend life expectancy. Researchers are focused on increasing health span — the period in which people can remain healthy, active and independent. That would mean finding ways to slow or alter age-related biological changes that accumulate over time and can make the body more vulnerable to illness.
“Aging has biology. This biology drives diseases,”
Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine in New York City, has argued that medicine could eventually address biological mechanisms linked to several disorders at once. Instead of handling each disease only after it develops, the approach would seek to influence processes that contribute to many age-related conditions.
Moving Beyond the Calendar
A person’s chronological age is easy to calculate, but it does not capture the full picture of health. Two people born in the same year can have very different levels of physical function, disease risk and resilience. Scientists are therefore trying to develop measures of biological aging that show how the body is changing beneath the surface.
Daniel Belsky, an associate professor of epidemiology at Columbia University’s Mailman School of Public Health and the Robert N. Butler Columbia Aging Center, said the central idea remains unproven in people. Experiments in animals have provided encouraging evidence, but human clinical trials have not yet demonstrated that changing aging biology can lengthen the years spent in good health.
“We don’t know yet whether we can really do this. But we do have an alignment of evidence to argue this is possible. And we now have a mobilization of resources to actually test it,”
In laboratory research involving organisms such as roundworms and mice, scientists have altered age-related biology through medications, exercise, calorie restriction and other strategies. These interventions can reduce or slow cellular changes associated with aging and have extended lifespan in animal studies. Whether similar results can be achieved safely and meaningfully in humans is a much more difficult question.
“For humans, we do not yet have clinical trial evidence that intervention on this biology to extend health span is possible,”
Belsky said. Still, he sees momentum building as the field develops the tools needed to run more informative human studies.
“But — and this is where I think the excitement comes from — we are seeing the ground shift in advancing toward those human clinical trials.”
Searching for Useful Biological Signals
A major obstacle is measurement. Chronic illnesses often emerge slowly, and a study testing whether an intervention begun at age 40 or 50 prevents disease could require participants to be followed for 20 or 30 years. Researchers need earlier indicators that can reliably show whether a treatment is likely to improve later health.
One area of focus is epigenetics, which concerns changes in gene regulation that do not alter the DNA sequence itself. Scientists can examine methyl groups, chemical tags attached to DNA, to look for patterns that may reflect the passage of time in the body.
Belsky’s Finding Aging Biomarkers by Searching Existing Trials, known as FAST, is collecting multi-omic data. This approach brings together several forms of biological information, including proteins, metabolites and epigenetic marks found in white blood cells. The goal is to identify indicators that respond when people undergo different interventions.
Such markers could eventually help researchers determine whether an exercise plan, medication, dietary change or another intervention is affecting biology in ways connected to healthier aging. However, an essential link has yet to be proven: changing a biomarker must be shown to predict a real-world benefit, such as delayed disease or a longer healthy lifespan.
If that relationship can be established, a biomarker could become a surrogate endpoint in a clinical trial. In practical terms, it would offer scientists an earlier measurable sign that a treatment is likely to lead to an important health outcome, rather than requiring decades of observation before drawing conclusions.
Longevity Clinics Enter the Conversation
Interest in the science is also shaping clinical care. Longevity clinics are beginning to offer detailed health assessments alongside more conventional preventive medicine. These programs may combine medical evaluations with broader testing intended to create a more individualized view of a patient’s current health and potential risks.
Mayo Clinic opened its Healthy Longevity Clinic in 2023. Singapore’s National University Health System has established a comparable program that pairs extensive assessment with personalized lifestyle or medical interventions.
The emergence of such clinics reflects increasing demand for prevention-focused care, but it also highlights the need for careful interpretation. A sophisticated test does not automatically establish that a particular treatment will improve long-term outcomes. The science of biological aging is advancing, yet many proposed measures and interventions still require rigorous clinical validation.
What the Research Could Mean
The most immediate lesson for patients is that longevity research should not be confused with a promise of a cure for aging. The field is investigating whether the processes associated with aging can be measured and influenced, not claiming that those questions have already been settled.
Its long-term value could lie in changing the timing of care. If researchers can identify reliable biological warning signs and show that targeted interventions improve health span, medicine may become better equipped to act before multiple chronic diseases take hold. For now, the work remains a scientific effort to turn a once-speculative possibility into evidence that can be tested in people.
Related Reading
Frequently Asked Questions
What is Can aging be treated like a disease?
Can aging be treated like a disease is the main topic of this guide. The article explains the context, practical details, and next steps readers should understand.
Why does Can aging be treated like a disease matter?
Can aging be treated like a disease matters because readers are looking for a useful answer, not just a short summary. Good content should match search intent and help them decide what to do next.